Theragnostic Talks
Very welcome to Theragnostic Talks by SAM Nordic, the one and only podcast about theragnostic. What is even theragnostic? And what does the future for it look like? In this podcast we will find out interesting science and get answers to curious questions by talking with true experts - clinicians, scientists and people from the industry.
And to guide you through these episodes – Annette Andrén and Gustav Widar.
Annette is driven by the transformation of science into value for patients. Her background as a chemical engineer - with focus on biochemistry - has led her to different positions such as country manager and market access director in the Nordics. She has been working both within a large variety of different therapy areas and with breakthrough treatments for inflammation and autoimmune diseases. What she likes the most is when she is able to help out in the identification of scientific opportunities for collaborations between Health care, Research and the Industry. She is currently senior medical science liaison at SAM Nordic.
Gustav has a background as a licensed medical physicist and has worked many years in the field of nuclear medicine – covering imaging, therapy and the production of radiopharmaceuticals. He is driven by making medical innovations a clinical reality – where it really benefits the patient care. A couple of years ago he changed from healthcare to industry, now medical science liaison at SAM Nordic.
- Update frequency
- every 13 days
- Average duration
- 40 minutes
- Episodes
- 23
- Years Active
- 2021 - 2023
Getting ready for theragnostics
We need to increase knowledge and awareness of theragnostics and now is the time. That's the view of Lucy Morgan, associate director of research and policy at the Health Policy Partnership. But how d…
Ready for theragnostics 2.0?
The world is on its way of taking a giant leap forward in the field of theragnostics. But are we ready for it? In this episode of Theragnostic Talks, we discuss readiness and the best way to raise aw…
What is it with FAPI?
What is it with FAPI and how does it work? In this episode of Theragnostic Talks, we take a closer look at the tracer that everyone’s talking about. The new theragnostic tracer targets the tumour env…
Prostate cancer and PSMA
How do we move forward with prostate imaging? In today’s episode of Theragnostic Talks, live from the EANM'22 Congress in Barcelona, we focus on PSMA-PET. How has PSMA-PET developed? Where are we reg…
EANM, today and tomorrow
What is EANM? What have been the most burning questions through the years and in what ways do we want to move forward in this area? Theragnostic Talks will be live in Barcelona to talk with the leadi…
EAU 22 Special Edition
LuTectomy – LuPSMA in the very early stage of prostate cancer – what were the initial results? What difference does it make, choosing the right PSMA tracer? And how should PSMA-PET be used, according…
Unlocking the potential of biomarkers in cancer treatment
Using biomarkers from a blood test: can that optimize the treatment for prostate cancer? Listen to Professor Henrik Grönberg, who recently received the award “Cancer Researcher of the Year in 2022” b…
A passionate journey with theragnostics
– I tell my kids that I am probably not going to see them a lot but I am going to do stuff for a lot of patients out there who are living miserable lives. That is my motivation, to make somebody feel…
Astatine-211 – Swedish start-up pushing cancer therapy to the next level with Emma Aneheim
Lack of evidence? Is consensus an option? – with Silke Gillessen
If you don´t have good evidence, the second best you can have is consensus from experts in the field. Meet Professor Silke Gillessen, one of the world´s leading experts in GU oncology and the lead or…
From academia to start-up
It takes persistence to turn preclinical research into business. And it takes great teamwork to make it successful. In this episode of Theragnostic Talks we get to meet Dr Frances Johnson and Dr Mich…
ProPSMA and TheraP – changing patient care - with Michael Hofman
Professor Michael Hofman has contributed to some of the most important progress for imaging and treatment of prostate cancer. And his collaborative approach has brought together multi-disciplinary ex…
The lucky, PET-addicted guy – with Stefano Fanti
By collaboration we can improve the scientific results and really make a difference. Don't miss this episode with the committed professor Stefano Fanti, devoted to his mission and always eager to spr…
Turned family loss to stronger patient voice – with Simone Leyden
When Simone Leyden lost her 34 year old sister in a rare GI cancer she and her brother John decided to start a foundation. What struck them, when their sister was struggling, was that there was a hug…
”This is the theragnostic breakthrough” – with Oliver Sartor, Bernd Krause and Ken Hermann
We gathered up with Oliver Sartor, Bernd Krause and Ken Hermann, co-authors of the VISION study, to talk about how it will impact the treatment of prostate cancer. The VISION study is the first inter…
ImmunoPET, predicting response to therapy - with Anna Wu
What is immunoPET and radio immunotherapy? Meet Anna Wu, professor at City of Hope and research professor at UCLA, California. She explains why antibodies can be used instead of small molecules or pe…
Renaissance for radioligand therapy - with Germo Gericke
In 5 to 10 years we are going to use theragnostics predominantly in combination with other therapies. Why? Because it gives us the opportunity to treat cancer in a totally different way. It's also a …
The PSMA take off - with Professor Louise Emmett
What professor Louise Emmett really loves is research. As a doctor, she says, you are able to change the lives for some people. With clinical research you can change the lives for millions of people.…
Kill them all - with Dr Oliver Sartor
What are the challenges for theragnostic to be successful in the future? And how can we turn theragnostic innovations into successful and available therapies? In this episode of Theragnostic Talks we…
S01E03 Christian Behrenbruch
“For nuclear medicine to be widely successful you have to care about people everywhere. We need to come up with solutions that make nuclear medicine really accessible for everyone. And the reason why…